Physicians and Industry Respond to Recent Vertebroplasty Studies
In August 2009, vertebral compression fracture treatment was dealt an unexpected blow when The New England Journal of Medicine published two articles that detailed prospective randomized controlled trials in which vertebroplasty did not result in a statistically significant clinical benefit over a sham procedure. The spinal community responded quickly to these articles, pointing out shortcomings of the two trials.
You may also be interested in...
Once considered the high flying segment of the musculoskeletal industry, the spine industry has finally hit a wall as procedure volumes stall, implant prices tumble, and payors push back on authorizing expensive operations for back pain such as spinal fusion. As economic woes heighten, hand in hand with persistent unemployment just as health care and regulatory reforms kick in, many left the North American Spine Society meeting in early October wondering where the bright spots are in this industry.
Brief summaries of recent medtech market and industry developments. This month we cover results from the EVEREST II trial on the MitraClip percutaneous mitral valve repair system, CareFusion's acquisition of Medegen, Sanofi and Agamatrix's glucose monitoring deal and Myriad Genetics' unfavorable patent ruling.
Just six months removed from Cardinal Health, CareFusion is making headlines with new products, anti-trust lawsuits and signficant acquisitions. The three individual events reflect the aggressive attitude CareFusion executives intend to carry now that they’re free from Cardinal Health.